Fig. 2 Consortia: Who and why? A total of 369 consortia were studied. (A) Sectors that initiated a consortium. (B) Growth of consortia by top three initiating sectors (government, third-party, and industry). (C) Sectors intended to benefit by consortium activities (n = 369), by initiating sector. (D) Growth of consortia focused on advancing device research. The color key applies to (A), (B), and (C). For consortia launched in Europe and North America, n = 208 and 144, respectively.
CREDIT: H. McDONALD/SCIENCE TRANSLATIONAL MEDICINE
Table 1. Disease-focused consortia. Products and locations for the top four diseases. Categorization of rare diseases was based on information in publicly available databases (24, 25). One caveat with this broad categorization is that therapeutic areas such as oncology, Alzheimer’s disease, and diabetes represent an aggregate of multiple subtypes, many of which may be rare diseases in themselves.
[CREDIT (background): Science collaborations map/computed by O. H. Beauchesne, using date from Scopus and Science-Metrix]
Supplementary Materials
www.sciencetranslationalmedicine.org/cgi/content/full/6/242/242cm6/DC1
Supplementary Methods
Table S1. Consortium Web sites
Table S2. Sectors or groups that initiate consortia through the development of strategic research agendas
Table S3. Examples of consortium output
References (28–31)
Additional Files
- Supplementary Material for:
Consortium Sandbox: Building and Sharing Resources
Mark D. Lim
*Corresponding author. E-mail: mlim{at}fastercures.org
Published 25 June 2014, Sci. Transl. Med. 6, 242cm6 (2014)
DOI: 10.1126/scitranslmed.3009024This PDF file includes:
- Supplementary methods.
- Table S1. Consortium Web sites.
- Table S2. Sectors or groups that initiate consortia through development of strategic research agendas.
- Table S3. Examples of consortium output.
[Download PDF]
